PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Links shared publicly online about this topic.

180
total visits

PENNSAID Viscous Solution Phase 2 clinical trial for osteoarthritis pain meets primary endpoint

Nuvo Research Inc., a specialty pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced receipt from Mallinckrodt Inc., a Covidien company (Covidien), of top-line results from a Phase 2 study conducted by Covidien, of twice-daily administration of PENNSAID Viscous Solution (topical diclofenac sodium viscous solution) 2% w/w, previously referred to as PENNSAID Gel.

View full resource at news-medical.net

Tags: Pain, Osteoarthritis, Osteoarthritis Medication, Rheumatoid Arthritis Medication, Pharma, Phase 2 Clinical Trial, Clinical Trial